Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 287

1.

A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.

Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium.

Eur Urol. 2013 May;63(5):927-35. doi: 10.1016/j.eururo.2012.09.007. Epub 2012 Sep 11.

PMID:
23040208
[PubMed - indexed for MEDLINE]
2.

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.

Greenspan SL, Nelson JB, Trump DL, Resnick NM.

Ann Intern Med. 2007 Mar 20;146(6):416-24.

PMID:
17371886
[PubMed - indexed for MEDLINE]
3.

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007. Epub 2012 Dec 19.

PMID:
23265571
[PubMed - indexed for MEDLINE]
4.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of monthly ibandronate in men with low bone density.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.

Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034. Epub 2010 Jan 6.

PMID:
20060082
[PubMed - indexed for MEDLINE]
6.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
[PubMed - indexed for MEDLINE]
7.

Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.

Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ.

J Bone Miner Res. 2006 Feb;21(2):300-6. Epub 2005 Oct 24.

PMID:
16418786
[PubMed - indexed for MEDLINE]
8.

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.

Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM.

J Clin Oncol. 2008 Sep 20;26(27):4426-34. doi: 10.1200/JCO.2007.15.1233.

PMID:
18802155
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.

J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207. Epub 2009 Jun 1.

PMID:
19487264
[PubMed - indexed for MEDLINE]
10.
11.

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.

J Clin Endocrinol Metab. 2004 Jul;89(7):3319-25.

PMID:
15240609
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.

PMID:
20499357
[PubMed - indexed for MEDLINE]
13.

Prevention of bone loss after withdrawal of tamoxifen.

Cohen A, Fleischer JB, Johnson MK, Brown IN, Joe AK, Hershman DL, McMahon DJ, Silverberg SJ.

Endocr Pract. 2008 Mar;14(2):162-7.

PMID:
18308653
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.

Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.

Hinyokika Kiyo. 2008 Apr;54(4):261-6.

PMID:
18516917
[PubMed - indexed for MEDLINE]
Free Article
15.

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.

Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ; Alendronate Once-Weekly Study Group.

J Bone Miner Res. 2002 Nov;17(11):1988-96.

PMID:
12412806
[PubMed - indexed for MEDLINE]
16.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

PMID:
19549260
[PubMed - indexed for MEDLINE]
17.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
[PubMed - indexed for MEDLINE]
18.

The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.

Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.

J Bone Miner Metab. 2009;27(4):471-8. doi: 10.1007/s00774-009-0057-7. Epub 2009 Apr 3.

PMID:
19343272
[PubMed - indexed for MEDLINE]
19.

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.

Choi HJ, Im JA, Kim SH.

Maturitas. 2008 Jun 20;60(2):170-6. doi: 10.1016/j.maturitas.2008.05.003. Epub 2008 Jun 24.

PMID:
18572334
[PubMed - indexed for MEDLINE]
20.

Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.

Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.

Arch Dermatol. 2012 Mar;148(3):307-14. doi: 10.1001/archdermatol.2011.354. Epub 2011 Nov 21.

PMID:
22105813
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk